## Antonio Spanevello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4117466/publications.pdf

Version: 2024-02-01

242 papers

12,775 citations

23544 58 h-index 28275 105 g-index

246 all docs 246 docs citations

246 times ranked 13735 citing authors

#	Article	IF	CITATIONS
1	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. European Journal of Internal Medicine, 2020, 76, 14-20.	1.0	980
2	Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD. New England Journal of Medicine, 2014, 371, 1285-1294.	13.9	526
3	Dissociation between Airway Inflammation and Airway Hyperresponsiveness in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 4-9.	2.5	478
4	A European Respiratory Society technical standard: exhaled biomarkers in lung disease. European Respiratory Journal, 2017, 49, 1600965.	3.1	432
5	An electronic nose in the discrimination ofÂpatients with asthma and controls. Journal of Allergy and Clinical Immunology, 2007, 120, 856-862.	1.5	399
6	An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer, 2009, 64, 166-170.	0.9	357
7	Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. European Respiratory Journal, 2012, 40, 1430-1442.	3.1	346
8	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. European Respiratory Journal, 2020, 56, 2001398.	3.1	273
9	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. European Respiratory Journal, 2017, 49, 1700387.	3.1	233
10	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2013, 42, 169-179.	3.1	226
11	Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respiratory Medicine, the, 2019, 7, 402-416.	5.2	225
12	Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. European Respiratory Journal, 2008, 33, 411-418.	3.1	220
13	Induced Sputum Cellularity. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1172-1174.	2.5	199
14	European Union Standards for Tuberculosis Care. European Respiratory Journal, 2012, 39, 807-819.	3.1	188
15	Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal, 2007, 30, 623-626.	3.1	179
16	Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. Pulmonology, 2020, 26, 233-240.	1.0	178
17	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal, 2009, 33, 871-881.	3.1	163
18	Tuberculosis elimination: theory and practice in Europe. European Respiratory Journal, 2014, 43, 1410-1420.	3.1	148

#	Article	IF	CITATIONS
19	Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax, 1998, 53, 583-585.	2.7	147
20	Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. European Respiratory Journal, 2013, 41, 1386-1392.	3.1	145
21	Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. European Respiratory Journal, 2002, 20, 19S-23s.	3.1	136
22	Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 910-920.	2.7	136
23	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. Emerging Infectious Diseases, 2020, 26, 2709-2712.	2.0	133
24	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. European Respiratory Journal, 2008, 31, 1155-1159.	3.1	131
25	Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. European Respiratory Journal, 2017, 50, 1700451.	3.1	130
26	Fibre types in skeletal muscles of chronic obstructive pulmonary disease patients related to respiratory function and exercise tolerance. European Respiratory Journal, 1997, 10, 2853-2860.	3.1	129
27	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 2020, 92, S15-S25.	1.5	126
28	An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls. Lung Cancer, 2012, 75, 326-331.	0.9	117
29	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. European Respiratory Journal, 2019, 54, 1901522.	3.1	113
30	Airway responsiveness to methacholine: effects of deep inhalations and airway inflammation. Journal of Applied Physiology, 1999, 87, 567-573.	1.2	111
31	Electrocardiographic features of patients with COVID-19 pneumonia. European Journal of Internal Medicine, 2020, 78, 101-106.	1.0	111
32	Estimation of Minimal Clinically Important Difference in EQ-5D Visual Analog Scale Score After Pulmonary Rehabilitation in Subjects With COPD. Respiratory Care, 2015, 60, 88-95.	0.8	101
33	Induced sputum to assess airway inflammation: a study of reproducibility. Clinical and Experimental Allergy, 1997, 27, 1138-1144.	1.4	93
34	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 2016, 47, 1235-1243.	3.1	92
35	Airway inflammation in patients affected by obstructive sleep apnea syndrome. Respiratory Medicine, 2004, 98, 25-28.	1.3	91
36	The one repetition maximum test and the sit-to-stand test in the assessment of a specific pulmonary rehabilitation program on peripheral muscle strength in COPD patients. International Journal of COPD, 2015, 10, 2423.	0.9	91

#	Article	IF	Citations
37	SARS-CoV-2 vaccines: Lights and shadows. European Journal of Internal Medicine, 2021, 88, 1-8.	1.0	90
38	Systemic and airway inflammation in sleep apnea and obesity: the role of ICAM-1 and IL-8. Translational Research, 2010, 155, 35-43.	2.2	89
39	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. European Respiratory Journal, 2020, 56, 2001727.	3.1	89
40	The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respiratory Research, 2010, 11, 132.	1.4	87
41	Classifying new anti-tuberculosis drugs: rationale and future perspectives. International Journal of Infectious Diseases, 2017, 56, 181-184.	1.5	82
42	Bronchoalveolar lavage, sputum and exhaled clinically relevant inflammatory markers: values in healthy adults. European Respiratory Journal, 2007, 30, 769-781.	3.1	81
43	Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respiratory Medicine,the, 2020, 8, 671-680.	<b>5.</b> 2	81
44	European Respiratory Society statement on long COVID follow-up. European Respiratory Journal, 2022, 60, 2102174.	3.1	81
45	Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. International Journal of Tuberculosis and Lung Disease, 2021, 25, 797-813.	0.6	78
46	Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). European Journal of Pharmacology, 2004, 505, 169-175.	1.7	76
47	Tuberculosis elimination: where are we now?. European Respiratory Review, 2018, 27, 180035.	3.0	76
48	Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review. International Journal of Molecular Sciences, 2016, 17, 373.	1.8	75
49	IL-2, TNF-α, and Leptin: Local Versus Systemic Concentrations in NSCLC Patients. Oncology Research, 2006, 16, 375-381.	0.6	74
50	Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thrombosis Research, 2003, 112, 203-207.	0.8	70
51	Induced sputum in children: feasibility, repeatability, and relation of findings to asthma severity. Thorax, 2000, 55, 768-774.	2.7	69
52	3p Microsatellite Signature in Exhaled Breath Condensate and Tumor Tissue of Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 337-341.	<b>2.</b> 5	69
53	Comparison of effectiveness and safety of imipenem/clavulanate-versusmeropenem/clavulanate-containing regimens in the treatment of MDR-ÂandÂXDR-TB. European Respiratory Journal, 2016, 47, 1758-1766.	3.1	69
54	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. European Respiratory Journal, 2008, 31, 904-905.	3.1	67

#	Article	IF	Citations
55	Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis: The Same Disease?. Clinical Infectious Diseases, 2012, 54, 1379-1380.	2.9	67
56	New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Research, 2015, 1, 00010-2015.	1.1	65
57	Exhaled pH, exhaled nitric oxide, and induced sputum cellularity in obese patients with obstructive sleep apnea syndrome. Translational Research, 2008, 151, 45-50.	2.2	64
58	COVID-19. Hypertension, 2020, 76, 294-299.	1.3	64
59	Efficacy of pulmonary rehabilitation in chronic respiratory failure (CRF) due to chronic obstructive pulmonary disease (COPD): The Maugeri Study. Respiratory Medicine, 2007, 101, 2447-2453.	1.3	60
60	Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. European Respiratory Journal, 2018, 52, 1800934.	3.1	59
61	Recent developments in the diagnosis and management of tuberculosis. Npj Primary Care Respiratory Medicine, 2016, 26, 16078.	1.1	58
62	Comparison of Two Methods of Processing Induced Sputum: Selected versus Entire Sputum. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 665-668.	2.5	57
63	Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. European Journal of Internal Medicine, 2020, 75, 15-18.	1.0	56
64	Characteristics and treatment regimens across ERS SHARP severe asthma registries. European Respiratory Journal, 2020, 55, 1901163.	3.1	56
65	Convergent Sets of Data from In Vivo and In Vitro Methods Point to an Active Role of Hsp60 in Chronic Obstructive Pulmonary Disease Pathogenesis. PLoS ONE, 2011, 6, e28200.	1.1	55
66	Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. Respiratory Medicine, 2020, 166, 105947.	1.3	55
67	Inflammation, Oxidative Stress and Systemic Effects in Mild Chronic Obstructive Pulmonary Disease. International Journal of Immunopathology and Pharmacology, 2007, 20, 753-763.	1.0	54
68	Exhaled NO and iNOS expression in sputum cells of healthy, obese and OSA subjects. Journal of Internal Medicine, 2008, 263, 70-78.	2.7	54
69	Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae. European Respiratory Journal, 2019, 53, 1802184.	3.1	51
70	A pilot study of nurse-led, home monitoring for patients with chronic respiratory failure and with mechanical ventilation assistance. Journal of Telemedicine and Telecare, 2006, 12, 337-342.	1.4	49
71	Addressing unmet needs in understanding asthma mechanisms. European Respiratory Journal, 2017, 49, 1602448.	3.1	47
72	Practical considerations for spirometry during the COVID-19 outbreak: Literature review and insights. Pulmonology, 2021, 27, 438-447.	1.0	47

#	Article	IF	Citations
73	Economic analysis of two structured treatment and teaching programs on asthma. Allergy: European Journal of Allergy and Clinical Immunology, 1996, 51, 313-319.	2.7	46
74	Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence: Table 1–. European Respiratory Journal, 2013, 42, 288-290.	3.1	45
75	Effects of Pulmonary Rehabilitation in Patients with Non-Cystic Fibrosis Bronchiectasis: A Retrospective Analysis of Clinical and Functional Predictors of Efficacy. Respiration, 2015, 89, 525-533.	1.2	45
76	Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?. Jornal Brasileiro De Pneumologia, 2016, 42, 374-385.	0.4	45
77	Improving the TB case management: the International Standards for Tuberculosis care. European Respiratory Journal, 2006, 28, 687-690.	3.1	44
78	Development of a Barthel Index based on dyspnea for patients with respiratory diseases. International Journal of COPD, 2016, 11, 1199.	0.9	44
79	Minimum Clinically Important Difference in 30-s Sit-to-Stand Test After Pulmonary Rehabilitation in Subjects With COPD. Respiratory Care, 2019, 64, 1261-1269.	0.8	42
80	Attenuation of induced bronchoconstriction in healthy subjects: effects of breathing depth. Journal of Applied Physiology, 2005, 98, 817-821.	1.2	41
81	Daytime PaO2 in OSAS, COPD and the combination of the two (overlap syndrome). Respiratory Medicine, 2013, 107, 310-316.	1.3	41
82	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. International Journal of Infectious Diseases, 2019, 83, 72-76.	1.5	41
83	The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study. Lancet Respiratory Medicine,the, 2022, 10, 661-668.	<b>5.</b> 2	41
84	Exhaled matrix metalloproteinase-9 (MMP-9) in different biological phenotypes of asthma. European Journal of Internal Medicine, 2014, 25, 92-96.	1.0	40
85	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later. European Journal of Internal Medicine, 2021, 93, 28-34.	1.0	40
86	Predictors of non-invasive ventilation tolerance in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2011, 303, 114-118.	0.3	39
87	Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair® In the Management of Asthma) study. Allergy, Asthma and Clinical Immunology, 2019, 15, 65.	0.9	39
88	Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2064-2076.	2.7	39
89	Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 1155.	0.9	38
90	Antibiotic Treatment of Severe Exacerbations of Chronic Obstructive Pulmonary Disease with Procalcitonin: A Randomized Noninferiority Trial. PLoS ONE, 2015, 10, e0118241.	1.1	38

#	Article	IF	Citations
91	Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine. European Journal of Internal Medicine, 2021, 90, 111-113.	1.0	38
92	Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension. BMC Pulmonary Medicine, 2008, 8, 20.	0.8	37
93	Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. International Journal of Infectious Diseases, 2015, 32, 101-104.	1.5	36
94	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. Clinical Infectious Diseases, 2008, 46, 958-959.	2.9	35
95	WHO strategies for the programmatic management of drug-resistant tuberculosis. Expert Review of Respiratory Medicine, 2016, 10, 991-1002.	1.0	34
96	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2016, 62, 1188.2-1190.	2.9	34
97	COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the "Spike effect". European Journal of Internal Medicine, 2022, 103, 23-28.	1.0	32
98	Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients. Respiratory Research, 2019, 20, 145.	1.4	31
99	MDR-TB and XDR-TB: drug resistance and treatment outcomes. European Respiratory Journal, 2009, 34, 778-779.	3.1	30
100	History of Tuberculosis and Drug Resistance. New England Journal of Medicine, 2013, 368, 88-90.	13.9	30
101	Frequent coexistence of chronic heart failure and chronic obstructive pulmonary disease in respiratory and cardiac outpatients: Evidence from SUSPIRIUM, a multicentre Italian survey. European Journal of Preventive Cardiology, 2017, 24, 567-576.	0.8	30
102	Relationship between diabetes and respiratory diseasesâ€"Clinical and therapeutic aspects. Pharmacological Research, 2018, 137, 230-235.	3.1	30
103	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. Journal of Infection, 2019, 78, 35-39.	1.7	30
104	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). World Allergy Organization Journal, 2020, 13, 100464.	1.6	30
105	Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology, 2021, 27, 403-412.	1.0	30
106	Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2020, 24, 700-705.	0.6	29
107	Effect of methacholine challenge on cellular composition of sputum induction. Thorax, 1999, 54, 37-39.	2.7	28
108	Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 1191.	0.9	28

#	Article	IF	CITATIONS
109	Tuberculosis in the time of COVID-19: quality of life and digital innovation. European Respiratory Journal, 2020, 56, 2001998.	3.1	28
110	Prognostic value of Exhaled Microsatellite alterations at 3p in NSCLC patients. Lung Cancer, 2009, 64, 334-340.	0.9	27
111	Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: How hot is the link?. Lung Cancer, 2010, 67, 108-113.	0.9	26
112	Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial. Lancet Respiratory Medicine, the, 2015, 3, 109-119.	5.2	25
113	Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. European Respiratory Journal, 2019, 53, 1900217.	3.1	25
114	Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patients. Pulmonology, 2021, 27, 452-455.	1.0	25
115	The need for pulmonary rehabilitation following tuberculosis treatment. International Journal of Tuberculosis and Lung Disease, 2020, 24, 720-722.	0.6	25
116	Pulmonary Rehabilitation and Asthma. Frontiers in Pharmacology, 2020, 11, 542.	1.6	24
117	Menopausal asthma: a new biological phenotype?. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1306-1312.	2.7	23
118	<p>Minimal Clinically Important Difference in Barthel Index Dyspnea in Patients with COPD</p> . International Journal of COPD, 2020, Volume 15, 2591-2599.	0.9	22
119	Management of chronic refractory cough in adults. European Journal of Internal Medicine, 2020, 81, 15-21.	1.0	22
120	Validation of the surveillance system for new cases of tuberculosis in a province of Northern Italy. European Respiratory Journal, 1995, 8, 1252-1258.	3.1	21
121	Multi and extensively drug-resistant pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 2018, 24, 244-252.	1.2	21
122	Drug-resistant tuberculosis among foreign-born persons in Italy: Table 1–. European Respiratory Journal, 2012, 40, 497-500.	3.1	20
123	Decreased Maturation of Dendritic Cells in the Central Airways of COPD Patients Is Associated with VEGF, TGF-i¿½ and Vascularity. Respiration, 2014, 87, 234-242.	1.2	20
124	Airway inflammatory profile is correlated with symptoms in stable COPD: A longitudinal proofâ€ofâ€concept cohort study. Respirology, 2020, 25, 80-88.	1.3	20
125	Heterogeneity of pulmonary rehabilitation: like apples and oranges - both healthy fruit. European Respiratory Journal, 2014, 43, 1223-1226.	3.1	19
126	Models of Respiratory Infections: Virus-Induced Asthma Exacerbations and Beyond. Allergy, Asthma and Immunology Research, 2015, 7, 525.	1.1	19

#	Article	IF	CITATIONS
127	Changes in sputum composition during 15min of sputum induction in healthy subjects and patients with asthma and chronic obstructive pulmonary disease. Respiratory Medicine, 2007, 101, 1543-1548.	1.3	18
128	Management and outcomes of post-acute COVID-19 patients in Northern Italy. European Journal of Internal Medicine, 2020, 78, 159-160.	1.0	18
129	Joint effect of heart failure and coronary artery disease on the risk of death during hospitalization for COVID-19. European Journal of Internal Medicine, 2021, 89, 81-86.	1.0	18
130	Severe asthma: One disease and multiple definitions. World Allergy Organization Journal, 2021, 14, 100606.	1.6	18
131	Sputum induced cellularity in a group of traffic policemen. Science of the Total Environment, 2006, 367, 433-436.	3.9	17
132	Repeated virus identification in the airways of patients with mild and severe asthma during prospective follow-up. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1099-1106.	2.7	17
133	Six-Minute Walking Distance Improvement after Pulmonary Rehabilitation Is Associated with Baseline Lung Function in Complex COPD Patients: A Retrospective Study. BioMed Research International, 2013, 2013, 1-6.	0.9	17
134	Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD. Monaldi Archives for Chest Disease, 2018, 88, 886.	0.3	17
135	Effectiveness of a Pulmonary Rehabilitation Program on Persistent Asthma Stratified for Severity. Respiratory Care, 2019, 64, 1523-1530.	0.8	17
136	When kidneys and lungs suffer together. Journal of Nephrology, 2019, 32, 699-707.	0.9	17
137	Chronic cough in adults. European Journal of Internal Medicine, 2020, 78, 8-16.	1.0	17
138	Bronchoalveolar lavage causes decrease in PaO2, increase in $(A-\hat{l}\pm)$ gradient value and bronchoconstriction in asthmatics. Respiratory Medicine, 1998, 92, 191-197.	1.3	16
139	Pulmonary Rehabilitation in COPD: A Reappraisal (2008–2012). Pulmonary Medicine, 2013, 2013, 1-8.	0.5	16
140	Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry. Journal of Cardiovascular Development and Disease, 2022, 9, 15.	0.8	16
141	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). Frontiers in Medicine, 2020, 7, 572485.	1.2	15
142	Exhaled Inflammatory Markers in Aspirin-Induced Asthma Syndrome. American Journal of Rhinology & Allergy, 2007, 21, 542-547.	2.3	14
143	Exercise capacity and comorbidities in patients with obstructive sleep apnea. Journal of Clinical Sleep Medicine, 2020, 16, 531-538.	1.4	14
144	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal, 2021, 14, 100509.	1.6	14

#	Article	IF	CITATIONS
145	Blood pressure increase during hospitalization for COVID-19. European Journal of Internal Medicine, 2022, 104, 110-112.	1.0	13
146	Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998–2000. European Respiratory Journal, 2003, 21, 129-134.	3.1	12
147	Telemedicine and home care: controversies and opportunities. Breathe, 2006, 3, 148-158.	0.6	12
148	Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients. European Journal of Internal Medicine, 2018, 47, 82-86.	1.0	12
149	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. European Respiratory Journal, 2020, 55, 1901908.	3.1	11
150	Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2009, 64, 879-883.	1.3	10
151	Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy: Figure 1–. European Respiratory Journal, 2012, 39, 1263-1266.	3.1	10
152	Aging and airway inflammation. Aging Clinical and Experimental Research, 2013, 25, 239-245.	1.4	10
153	Exhaled breath temperature in NSCLC: Could be a new non-invasive marker?. Medical Oncology, 2014, 31, 952.	1.2	10
154	Management of drug resistantTB in patients with HIV co-infection. Expert Opinion on Pharmacotherapy, 2015, 16, 2737-2750.	0.9	10
155	Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta2-agonists formulations in chronic obstructive pulmonary disease. Respiratory Medicine, 2018, 143, 74-81.	1.3	10
156	Adherence to Continuous Positive Airway Pressure in patients with Obstructive Sleep Apnoea. A ten year real life study. Respiratory Medicine, 2019, 150, 95-100.	1.3	10
157	Current developments and future directions in COPD. European Respiratory Review, 2020, 29, 200289.	3.0	10
158	Characteristics of COVID-19 Pneumonia Survivors With Resting Normoxemia and Exercise-Induced Desaturation. Respiratory Care, 2021, 66, 1657-1664.	0.8	10
159	Electrocardiographic features of patients with COVID-19: One year of unexpected manifestations. European Journal of Internal Medicine, 2022, 95, 7-12.	1.0	10
160	A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries. Pulmonology, 2022, 28, 44-58.	1.0	10
161	Five-Year Survival of Stage IIIA-IIIB (Non-N3) Non-Small Cell Lung Cancer Patients after Platinum/Gemcitabine Induction Chemotherapy and Surgery. Journal of Chemotherapy, 2010, 22, 191-196.	0.7	9
162	The new frontiers of rehabilitation medicine in people with chronic disabling illnesses. European Journal of Internal Medicine, 2019, 61, 1-8.	1.0	9

#	Article	IF	Citations
163	Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry. Expert Review of Respiratory Medicine, 2021, 15, 419-424.	1.0	9
164	Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients. Acta Otorhinolaryngologica Italica, 2020, 40, 435-443.	0.7	9
165	Impact of COVID-19 on patients with asthma. International Journal of Tuberculosis and Lung Disease, 2020, 24, 1217-1219.	0.6	9
166	Aging and Induced-Sputum Cells. Chest, 2005, 128, 4049-4050.	0.4	8
167	Microsatellite alterations suggestive of organâ€specific asthma and atopy in exhaled breath condensate. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 404-405.	2.7	8
168	Pulmonary rehabilitation: promising nonpharmacological approach for treating asthma?. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 80-84.	1.1	8
169	Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. Applied Sciences (Switzerland), 2020, 10, 2734.	1.3	8
170	The multidrug-resistant tuberculosis threat: old problems and new solutions. Journal of Thoracic Disease, 2015, 7, E354-60.	0.6	8
171	Chronic bronchial asthma from challenge to treatment: epidemiology and social impact. Thorax, 2000, 55, 57S-58.	2.7	7
172	Ripped from the headlines: how can we harness communications to control TB?. European Respiratory Journal, 2007, 30, 194-198.	3.1	7
173	Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis. Journal of Asthma, 2020, 57, 1365-1371.	0.9	7
174	Minimal clinically important difference of the 6-min walking test in patients with asthma. International Journal of Tuberculosis and Lung Disease, 2021, 25, 215-221.	0.6	7
175	Pulmonary rehabilitation in patients with interstitial lung diseases: Correlates of success. Respiratory Medicine, 2021, 185, 106473.	1.3	7
176	Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. Jornal Brasileiro De Pneumologia, 2021, 47, e20210076.	0.4	7
177	Effects of intradermal injection of atrial natriuretic peptide British Journal of Clinical Pharmacology, 1995, 40, 283-285.	1.1	6
178	Consensus Not Yet Reached on Key Drugs for Extensively Drugâ€Resistant Tuberculosis Treatment. Clinical Infectious Diseases, 2009, 49, 315-316.	2.9	6
179	Validity and reproducibility of morphologic analysis of nasal secretions obtained using ultrasonic nebulization of hypertonic solution. Annals of Allergy, Asthma and Immunology, 2007, 99, 232-235.	0.5	5
180	Is the exhaled breath temperature in lung cancer influenced by airways neoangiogenesis or by inflammation?. Medical Oncology, 2015, 32, 237.	1.2	5

#	Article	IF	CITATIONS
181	Research highlights from the 2017 ERS International Congress: airway diseases in focus. ERJ Open Research, 2018, 4, 00163-2017.	1.1	5
182	Is there a role for biomarkers in pulmonary rehabilitation?. Biomarkers in Medicine, 2018, 12, 1069-1072.	0.6	5
183	The pleura and the endocrine system. European Journal of Internal Medicine, 2020, 72, 34-37.	1.0	5
184	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment. Internal and Emergency Medicine, 2022, 17, 299-302.	1.0	5
185	Combined Use of Electrocardiography and Ultrasound to Detect Cardiac and Pulmonary Involvement after Recovery from COVID-19 Pneumonia: A Case Series. Journal of Cardiovascular Development and Disease, 2021, 8, 133.	0.8	5
186	From the authors:. European Respiratory Journal, 2010, 35, 938-940.	3.1	4
187	<i>In vitro</i> susceptibility testing and totally drug-resistant tuberculosis. European Respiratory Journal, 2013, 42, 292-292.	3.1	4
188	Italian survey on prevalence and disease management of chronic heart failure and chronic obstructive pulmonary disease comorbidity in ambulatory patients. SUSPIRIUM study rationale and design. Monaldi Archives for Chest Disease, 2015, 82, 29-34.	0.3	4
189	Airway inflammatory phenotypes: Making sputum cell evaluation more accessible for clinical use. Clinical Respiratory Journal, 2018, 12, 1989-1990.	0.6	4
190	Airways diseases: asthma, COPD and chronic cough highlights from the European Respiratory Society Annual Congress 2018. Journal of Thoracic Disease, 2018, 10, S2992-S2997.	0.6	4
191	The respiratory rehabilitation Maugeri network service reconfiguration after 1 year of COVID-19. Monaldi Archives for Chest Disease, $2021, 91, \ldots$	0.3	4
192	The Role of Blood Gas Analysis in the Post-Acute Phase of COVID-19 Pneumonia. Archivos De Bronconeumologia, 2021, , .	0.4	4
193	Tuberculosis sequelae assessment and rehabilitation. , 0, , 326-342.		4
194	Long-Term Survival in Patients with Post-Operative Atrial Fibrillation after Cardiac Surgery: Analysis from a Prospective Cohort Study. Journal of Cardiovascular Development and Disease, 2021, 8, 169.	0.8	4
195	Shortened questionnaires to assess anxiety and depression during in-hospital rehabilitation: clinical validation and cutoff scores. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2627-2633.	1.0	3
196	Research highlights from the 2018 European Respiratory Society International Congress: airway disease. ERJ Open Research, 2019, 5, 00225-2018.	1.1	3
197	ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly. ERJ Open Research, 2020, 6, 00341-2019.	1.1	3
198	The 5-Repetition Sit-to-Stand Test as an Outcome Measure for Pulmonary Rehabilitation in Subjects With Asthma. Respiratory Care, 2021, 66, 769-776.	0.8	3

#	Article	IF	Citations
199	Minimal clinically important difference in 30 second sit-to-stand test after pulmonary rehabilitation in patients with COPD. , $2018,  ,  .$		3
200	Implementation of a real-world based ICF set for the rehabilitation of respiratory diseases: a pilot study. Minerva Medica, 2020, 111, 239-244.	0.3	3
201	Cardio-respiratory International Classification of Functioning, Disability and Health sets for inpatient rehabilitation: from theory to practice. European Journal of Physical and Rehabilitation Medicine, 2020, 56, 252-254.	1.1	3
202	Latex Allergy and Sensitization in Cities: A Survey in a Population at Risk. International Journal of Immunopathology and Pharmacology, 2006, 19, 821-830.	1.0	2
203	An Electronic Nose Discriminates between the Exhaled Breath of Patients with Pleural Malignant Mesothelioma and Healthy Controls, 2009, , .		2
204	Declaration on palliative care for MDR/XDR-TB [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1418-1419.	0.6	2
205	Eosinophilia in asthma: the easy way is not always the best. Lancet Respiratory Medicine, the, 2015, 3, 260-261.	5.2	2
206	Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment. Internal and Emergency Medicine, 2022, 17, 303-306.	1.0	2
207	Correlation between sputum and blood eosinophils in asthmatic and COPD patients with comorbidities , $2018,  ,  .$		2
208	Towards a practical clinical use of fractioned exhaled nitric oxide levels in chronic cough. Annals of Translational Medicine, 2016, 4, 357-357.	0.7	2
209	Epidemiology of TB. , 2012, , 14-25.		2
210	Towards a Better Phenotyping of Chronic Obstructive Pulmonary Diseases. Respiration, 2009, 78, 253-255.	1.2	1
211	Assessment and Management of Respiratory Dysfunction in Patients with Amyotrophic Lateral Sclerosis., 2012,,.		1
212	The use of roflumilast in COPD: a review. Monaldi Archives for Chest Disease, 2013, 79, .	0.3	1
213	Is bronchodilator the correct treatment for COPD subjects before EBUS?. Journal of Thoracic Disease, 2017, 9, S410-S413.	0.6	1
214	Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease. , 2015, , .		1
215	High-Flow Oxygen Therapy (HFOT) during training in COPD with chronic respiratory failure (CRF): a multicentre randomized controlled trial. , 2019, , .		1
216	Heart rate recovery in adult individuals with asthma. Monaldi Archives for Chest Disease, 2022, , .	0.3	1

#	Article	IF	CITATIONS
217	The fight against tobacco. Monaldi Archives for Chest Disease, 2013, 79, 5.	0.3	O
218	Assembly 5: airway diseases. Breathe, 2017, 13, 59-60.	0.6	0
219	The Barthel index-dyspnea a tool for respiratory rehabilitation: reply to the letter by Chuang [Letter of clarification]. International Journal of COPD, 2017, Volume 12, 813-815.	0.9	0
220	A new deal for the Monaldi Archives for Chest Disease. Monaldi Archives for Chest Disease, 2017, 87, 837.	0.3	0
221	Integrated care of chronic degenerative non-communicable diseases and rehabilitation: the odd couple?. Monaldi Archives for Chest Disease, 2017, 87, 818.	0.3	0
222	Accomplishments, engagements and new challenges for the Monaldi Archives for Chest Disease. Monaldi Archives for Chest Disease, 2019, 89, .	0.3	0
223	Tuberculosis Rehabilitation and Palliative Care. , 2021, , 275-281.		0
224	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis. , $2016$ , , .		0
225	Development of a Barthel index based on dyspnea for patients with respiratory diseases. , 2016, , .		0
226	$Effectiveness\ and\ safety\ of\ imipenem/clavulanate-\ versus\ meropenem/clavulanate-\ containing\ regimens\ in\ the\ treatment\ of\ multidrug\ resistant\ tuberculosis.\ ,\ 2016,\ ,\ .$		0
227	Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results. , 2017, , .		0
228	A rapid method to increase the clinical use of sputum inflammatory cells. , 2017, , .		0
229	Selection of patients from Pulmonary Rehabilitation (PR) to Disease Management (DM) programmes., 2017,,.		0
230	Predictors of continuous positive airway pressure adherence in obstructive sleep apnea syndrome., 2017,,.		0
231	Effectiveness of pulmonary rehabilitation programs on persistent asthma, 2018, , .		0
232	Outcomes of drug-resistant TB cases undergoing bedaquiline (BQ)-treatment and adjunctive surgery. , 2018, , .		0
233	What is the best frequency of exercise training in patients with moderate-to-severe COPD ?. , 2018, , .		0
234	Sputum and exhaled breath analysis. , 2019, , 187-193.		0

#	Article	IF	CITATIONS
235	Effects of Mepolizumab on symptoms, systemic and bronchial inflammation. , 2019, , .		0
236	Validation of a tool to assess daily active behaviour in COPD patients. , 2019, , .		0
237	Retrospective study on the combined use of voriconazole and prednisolone in the treatment of acute allergic bronchopulmonary aspergillosis (ABPA)., 2019,,.		O
238	Masterclass in airways disease: course report. Breathe, 2019, 15, e132-e134.	0.6	0
239	Effort tolerance and effectiveness of pulmonary rehabilitation in COPD patients with varying degrees of dyspnea during ADL. , 2020, , .		O
240	Asthma as a co-morbidity and cause of bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)., 2020,,.		0
241	Monitoring COPD patients according to the GOLD 2017 document: systemic and bronchial inflammation. , 2020, , .		0
242	Minimal clinically important difference in Barthel dyspnoea after pulmonary rehabilitation in patients with Chronic Obstructive Pulmonary Disease., 2020,,.		O